Your browser doesn't support javascript.
loading
Selective Noradrenaline Depletion in the Neocortex and Hippocampus Induces Working Memory Deficits and Regional Occurrence of Pathological Proteins.
Prinzi, Chiara; Kostenko, Anna; de Leo, Gioacchino; Gulino, Rosario; Leanza, Giampiero; Caccamo, Antonella.
Afiliação
  • Prinzi C; Department of Drug and Health Sciences, University of Catania, 95125 Catania, Italy.
  • Kostenko A; B.R.A.I.N. (Basic Research and Integrative Neuroscience) Laboratory for Neurogenesis and Repair, Department of Life Sciences, University of Trieste, 34100 Trieste, Italy.
  • de Leo G; SISSA, Scuola Internazionale Superiore di Studi Avanzati, 34136 Triste, Italy.
  • Gulino R; Department of Biomedical and Biotechnological Sciences, University of Catania, 95125 Catania, Italy.
  • Leanza G; Department of Drug and Health Sciences, University of Catania, 95125 Catania, Italy.
  • Caccamo A; Molecular Preclinical and Translational Imaging Research Centre-IMPRonTE, University of Catania, 95125 Catania, Italy.
Biology (Basel) ; 12(9)2023 Sep 21.
Article em En | MEDLINE | ID: mdl-37759663
Noradrenaline (NA) depletion occurs in Alzheimer's disease (AD); however, its relationship with the pathological expression of Tau and transactive response DNA-binding protein 43 (TDP-43), two major hallmarks of AD, remains elusive. Here, increasing doses of a selective noradrenergic immunotoxin were injected into developing rats to generate a model of mild or severe NA loss. At about 12 weeks post-lesion, dose-dependent working memory deficits were detected in these animals, associated with a marked increase in cortical and hippocampal levels of TDP-43 phosphorylated at Ser 409/410 and Tau phosphorylated at Thr 217. Notably, the total levels of both proteins were largely unaffected, suggesting a direct relationship between neocortical/hippocampal NA depletion and the phosphorylation of pathological Tau and TDP-43 proteins. As pTD43 is present in 23% of AD cases and pTau Thr217 has been detected in patients with mild cognitive impairment that eventually would develop into AD, improvement of noradrenergic function in AD might represent a viable therapeutic approach with disease-modifying potential.
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2023 Tipo de documento: Article